Prevention and Application of Vasopressin and its analogues on vasoplegic syndrome after cardiopulmonary bypass in heart valve replacement surgery

Prevention and Application of Pituitrin on vasoplegic syndrome after cardiopulmonary bypass in heart valve replacement surgery

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200065611

Enrollment

Unknown

Registered

2022-11-09

Start date

2022-11-09

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Valve Disease

Interventions

experimental group:Pituitrin intravenous infusion

control group:Intravenous infusion of normal saline

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1. Patients undergoing elective valve replacement surgery 2. Age 18-75 years old. 3. No other organ system dysfunction (liver, kidney, brain, lung, or blood system diseases).

Exclusion criteria

Exclusion criteria: Exclusion criteria : 1. Preoperative left ventricular ejection fraction(LVEF)<40%; 2. Preoperative application of cardiac assist devices (such as IABP, cardiac pacemaker, left ventricular assist device, etc.); 3. Patients need IABP or ECMO support after heart re-beating; 4. Patients died during the operation; 5. Researchers deemed it inappropriate or family members and patients refused to participate in the study.

Design outcomes

Primary

Measure	Time frame
Incidence;	—

Secondary

Measure	Time frame
vasoactive inotropic score;blood glucose;Lactate value;Urine output;Blood sodium;	—

Countries

China

Contacts

Public ContactSuchun Ding

Affiliated Yantai Yuhuangding Hospital, Medical College of Qingdao University

dd94207@163.com+86 535 6691999 81427

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026